SMMART® stands for Serial Measurements of Molecular and Architectural Responses to Therapy. It was given this name because repeated, or serial, measurements are taken from each patient, over time. The serial measurements allow researchers and treating oncologists to best understand each patient's cancer in great detail, and also to best individualize the treatments prescribed for each patient. The goal of the SMMART program is to develop new treatments for cancer that last longer (are more durable) and allow better quality of life (are more tolerable) for patients with advanced disease.

The SMMART team is comprised hundreds of scientists, including physician-scientists, clinicians, sample and imaging processing experts, data scientists, pharmacists, radiology, programmers and lab scientists.

The KDL participates by performing a variety of molecular tests including the GeneTrails Comprehensive Solid Tumor Panel on each sample.

Read more about the SMMART program.

The Knight Cancer Institute at Oregon Health & Science University is a pioneer in the field of precision cancer medicine. The institute's director, Brian Druker, M.D., helped prove it was possible to shut down just the cells that enable cancer to grow. This breakthrough has made once-fatal forms of the disease manageable and transformed how cancer is treated. The OHSU Knight Cancer Institute is the only National Cancer Institute-designated Cancer Center between Sacramento and Seattle – an honor earned only by the nation's top cancer centers. It is headquarters for one of the National Cancer Institute's largest research collaboratives, SWOG, in addition to offering the latest treatments and technologies as well as hundreds of research studies and clinical trials.

Learn More